Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24469242 | 0.91 | HDAC1 (0.37) | GABBR2GABBR1MAP4K4DRD2 | |
| SCHEMBL24469182 | 0.82 | PRKAA2 (0.39) | GABBR2GABBR1MAP4K4PRKAA2PTGS1 | |
| SCHEMBL24469245 | 0.78 | OPRL1 (0.35) | MAP4K4MCHR1 | |
| SCHEMBL24469252 | 0.74 | DRD2 (0.40) | DRD2ADORA2AMKNK1MKNK2HTR1B | |
| SCHEMBL30467658 | 0.69 | POLB (0.33) | — | |
| SCHEMBL24252315 | 0.69 | POLB (0.33) | — | |
| SCHEMBL24469173 | 0.69 | EGFR (0.33) | — | |
| SCHEMBL4837981 | 0.68 | ADORA2A (0.41) | NPC1TP53TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL24469184 | 0.68 | PRKDC (0.36) | — | |
| SCHEMBL1102314 | 0.67 | ALDH1A1 (0.40) | NPC1TP53TSHRRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-04 | — | — | US | disclosed |
| EP-4251273-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-04 | — | — | EP | disclosed |
| CN-116745284-A | Phthalazine derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112493-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | GABBR2 1434/4885GABBR1 1007/4885MAP4K4 2953/4885 |
| US-20240002371-A1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX2 | GABBR2 1364/4885GABBR1 1053/4885MAP4K4 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.